Nick joined Gamida Cell as Vice President of U.S. Cell Therapy Operations in October 2022, bringing 25 years of US and international experience in the pharmaceutical and biotech field including extensive experience in cell therapy quality and operations. Nick is responsible for U.S. Supply Chain, Logistics, and onboarding of new transplant centers, leading all aspects of the commercial end to end processes to assure a positive patient experience, including Chain of Identity (CoI) and Chain of Custody (CoC) management from CBU procurement and cell order through shipment of final product to transplant center customers. Prior to joining Gamida Cell, Nick was a Senior Consultant for over a year, guiding Gamida Cell on aspects of the BLA submission of Omisirge®, the first allogeneic stem cell transplant therapy to be FDA approved, including preparations for FDA pre-license inspection, leading the design and implementation of the end-to-end COI/COC process validation and the GDA-201 IND submission. Prior to consulting with Gamida Cell, Nick was at Kite Pharma, playing an instrumental role in the successful BLA submission of YESCARTA®, the first approved CAR-T therapy in lymphoma, and FDA pre-licensing inspection and responsible for completing all quality and operations requirements to successfully commercialize and onboard the initial 60 US Transplant Center sites in addition to programs and sites in Canada, EU, China, and Japan. Prior to Kite, Nick held increasing roles and responsibilities at Amgen, Baxter, and Alpha Therapeutics (Grifols). Nick received his B.S. from the University of La Verne.